Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evocalcet Dose-Adjustment Study for Hypercalcemia in Parathyroid Carcinoma or Primary Hyperparathyroidism
jRCT2080223628Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ASP7991 in hypercalcemia, parathyroid cancer and primary hyperparathyroidism (PHPT), sponsored by Kyowa Kirin. Started Aug 2017; status: completed.
02
Drugs
ASP7991
03
Conditions
hypercalcemiaparathyroid cancerprimary hyperparathyroidism (PHPT)
Beyond the preview
Go deeper on jRCT2080223628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223628.